Search Results

You are looking at 31 - 40 of 1,005 items for :

  • "community" x
  • Refine by Access: All x
Clear All
Full access

Alison Roos, Lucio Gordan, Michael Diaz, Anjan Patel, Matthew Fink, David Wenk, John Jiang, Janice Tam, Pratheesh Sathyan, and Phil Febbo

tissue biopsy-based biomarker testing and reflex testing dynamics to understand the current NSCLC biomarker testing scenario in a large US community practice. Methods: Patients with advanced NSCLC (n=250) who received care in a large US community

Full access

Dewilka Simons, Yolaine Jeune-Smith, Bruce Feinberg, Stephanie Fortier, and Ajeet Gajra

surveyed community hematologists/oncologists (cH/O) on their perceptions of the OlympiA trial data and the potential impact on their BRCA 1/2 testing habits in patients with early-stage BC. Methods : Between June and October 2021, practicing U.S. cH/O were

Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao

strengths. Data were used from a large community-based population of patients with cancer; therefore, the findings may better reflect FN risks in the real-world setting. The comprehensive clinical databases at KPSC allowed for detailed characterizations of

Full access

Jonas M Congelli, Rebecca Maniago, Stephanie Jou, Janet Donegan, and Ivy Altomare

documentation of NCCN Guideline concordant and NCCN preferred treatment regimens. We assessed patterns of concordant, preferred and non-preferred treatment regimen ordering at one large multi-site community practice. Methods : We reviewed all treatment orders

Full access

Rachel J Meadows, Anna Muraveva, Christina Bijou, Kate Shane-Carson, Coralia Balasca, Celia E Wills, Lisa D Yee, Electra D Paskett, and Tasleem J Padamsee

, community-based sample. Methods : This study uses data (collected Oct 2018–Aug 2019) from a survey that included measures of risk-management behavior, potential correlates, and information necessary to determine lifetime BC risk. Eligible participants were

Full access

Jeffrey Scott, Dean Slack, Lindsay Gingras, Marc Chioda, and Huan Huang

study aimed to assess the prevalence of HAEs and associated health care resource utilization among patients receiving chemotherapy for ES-SCLC in the community oncology setting. Methods : Adult patients with ES-SCLC included in the Integra Connect

Full access

Kaustav Chatterjee, Edward Drea, Robert Smith, Mei Xue, Hunter Lambert, Jeffrey Scott, Sorena Nadaf, Simon Blanc, Prateesh Varughese, and John Verniero

following chemotherapy [1] . However, no real-world data has been published that quantifies TLS risk factors by cancer type. Methods: The Integra database of 17 community oncology accounts was queried for patients ≥18 years of age having a TLS ICD10 code

Full access

Anne Shah, Jon Apple, Joanne Willey, Michael Ayars, Daniel Simmons, Dana Nickleach, Ganiat Mumuney, Manish Patel, and Kristen Brunskill

25 Nov 2020 to encourage testing for EGFR mutations in eligible patients with resectable NSCLC. This study evaluated real-world testing for EGFR, including the impact of guideline changes (before vs after 25 Nov 2020) on testing in the US community

Full access

Sydney Beache, Aimee James, Graham Colditz, and Courtney Harriss

Background : While lung cancer is a leading cause of death in the U.S., annual screening rates with low-dose Computed Tomography (LDCT) among eligible candidates remain low at 12.7%. The WUSTL research group began a community intervention to

Full access

Data adapted from Bergstrom et al. 1 Data based on reporting from 750 community oncology practices in the United States to McKesson Specialty Care Solutions. Adjuvant chemotherapy for breast cancer has evolved over several decades